Skip to main content

Edgewise Therapeutics, Inc.

corporate_fare Company Profile

Edgewise Therapeutics, Inc.

EWTX·NASDAQ·Life Sciences·CIK 0001710072

Edgewise discovers new medicines to improve the lives of people with serious muscle diseases. The company uses a proprietary, muscle-focused drug discovery platform that combines expertise in muscle biology and small molecule engineering. This platform utilizes custom-built high throughput and translatable systems to measure integrated muscle function in whole organ extracts. Its purpose is to identify small molecule precision medicines that regulate key proteins in muscle tissue, initially targeting rare neuromuscular and cardiac diseases. Edgewise has developed a library of novel sarcomere modulators with various pharmacological and pharmacokinetic properties that regulate disease-related muscle biology. The company is advancing multiple clinical-stage programs for muscular dystrophies and severe cardiac diseases, alongside several preclinical programs. Its muscular dystrophy program includes sevasemten, an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor. Sevasemten is designed to address contraction-induced muscle injury, which is the root cause of dystrophinopathies such as Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). These are rare and often debilitating diseases. Edgewise estimates approximately 35,000 individuals live with Duchenne and 12,000 individuals live with Becker in the US, EU-5, and Japan. There are currently no approved therapies for individuals with Becker. Sevasemten is designed to selectively limit injurious stress caused by the lack of dystrophin by moderating fast skeletal muscle myosin force development, thereby compensating for the absence of functional dystrophin.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for EWTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 8/10. Across its 12 most recent items scored 7 or higher, the top rating is 10/10, with 8 rated 8 or above. Recent SEC coverage for EWTX spans 10-Q, 8-K, 8-K/A, 10-K.

Recent high-impact activity:

  • Edgewise Jumps 12% on Report of Takeover Interest and Adviser-Led Sales Process
  • Edgewise Swings to $1.17B Profit on Sevasemten Sale, $1.74B Cash, Phase 3 HCM Trial by Year-End
  • Edgewise Q2 2026: $460.7M cash before Sevasemten close; $1.55B upfront received July 10; EDG-7500 Phase 3 on track for Q4
  • Edgewise Delivers Positive Phase 2 HCM Data and Q2 Results; Pro Forma Cash Hits $2B After Servier Deal
  • Edgewise Files Pro Forma Financials for $1.55B Sevasemten Sale to Servier

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$167.79M
Diluted EPS
-$1.63
Op. Cash Flow
-$143.82M
Free Cash Flow
-$144.07M
Operating Income
-$191.41M
Cash & Equivalents
$61.15M
Debt / Equity
0.00×
Shares Outstanding
106.25M sh
Source: 10-K · filed 2026-02-26 · accession 0001104659-26-020112

Short Interest & Short Volume

9.64 days to cover

FINRA reported short interest of 12,696,203 shares in EWTX as of the October 30, 2026 settlement, a 8.0% increase from the prior period — about 9.6 days to cover at its recent average daily volume. On November 20, 2026, 41.9% of EWTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)12,696,203 shares as of October 30, 2026
Change vs prior period▲ 8.0%
Days to cover9.64 at avg daily volume of 1,316,851
Daily short volume (FINRA facilities)41.9% of 280,836 shares on November 20, 2026
5-day average short volume47.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with E →
$39.91
52-week range · as of 2026-08-06 $12.3 – $48.4
Market cap
$4.37B
Volume
1.2M (0.8× avg)
3-mo avg 1.6M
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed EWTX - Latest Insights

EWTX
Nov 06, 2026, 11:47 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $43.18
Real-time Price: $39.91 info
Change: -$3.27 (-8%) info
Market Cap: $4.369B info
EWTX
Nov 04, 2026, 4:01 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $37.51
Real-time Price: $39.91 info
Change: +$2.40 (+6%) info
Market Cap: $4.369B info
EWTX
Aug 06, 2026, 8:05 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $44.95
Real-time Price: $39.91 info
Change: -$5.05 (-11%) info
Market Cap: $4.369B info
EWTX
Aug 06, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $44.95
Real-time Price: $39.91 info
Change: -$5.05 (-11%) info
Market Cap: $4.369B info
EWTX
Jul 16, 2026, 8:01 AM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $39.23
Real-time Price: $39.91 info
Change: +$0.675 (+2%) info
Market Cap: $4.369B info
EWTX
Jun 01, 2026, 8:51 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $43.15
Real-time Price: $39.91 info
Change: -$3.24 (-8%) info
Market Cap: $4.369B info
EWTX
Jun 01, 2026, 8:30 AM EDT
Source: PR Newswire
Importance Score:
10
Price at Filing: $34.35
Real-time Price: $39.91 info
Change: +$5.56 (+16%) info
Market Cap: $4.369B info
EWTX
May 07, 2026, 9:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $37.45
Real-time Price: $39.91 info
Change: +$2.45 (+7%) info
Market Cap: $4.369B info
EWTX
Feb 26, 2026, 8:05 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $29.84
Real-time Price: $39.91 info
Change: +$10.07 (+34%) info
Market Cap: $4.369B info
EWTX
Feb 26, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.20
Real-time Price: $39.91 info
Change: +$9.71 (+32%) info
Market Cap: $4.369B info
EWTX
Jan 20, 2026, 4:14 PM EST
Filing Type: 144
Importance Score:
8
Price at Filing: $28.73
Real-time Price: $39.91 info
Change: +$11.18 (+39%) info
Market Cap: $4.369B info
EWTX
Jan 15, 2026, 4:45 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $27.39
Real-time Price: $39.91 info
Change: +$12.52 (+46%) info
Market Cap: $4.369B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets